Q-omics provides the consensus-scored FNBP1 profile across patient tissues and cancer cell-line models. FNBP1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, FNBP1 is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, FNBP1 protein abundance shows 22,450 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, BLCA, and LSCC as cancer lineages where FNBP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FNBP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FNBP1 survival associations across molecular data types. FNBP1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FNBP1 RNA expression–survival associations across cancer types. High FNBP1 expression shows unfavorable associations in UVM and ACC, but favorable associations in CESC, SCLC, LUAD and HNSC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for FNBP1 RNA expression.
This table summarizes FNBP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in BLCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for FNBP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FNBP1 shows lower tumor expression in BLCA, COAD, THCA, LUAD and UCEC and higher tumor expression in KIRC. The BLCA box plot shows higher FNBP1 RNA expression in normal versus tumor tissue (log2 FC = −3.215, t-test p < 0.001).
This table shows molecular features associated with FNBP1 in patient tissues and cancer cell lines. In patient samples, FNBP1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, FNBP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and CNS.
